GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Ltd (NYSE:BHVN) » Definitions » Net Cash per Share
Switch to:

Biohaven (NYSE:BHVN) Net Cash per Share

: $0.43 (As of Sep. 2022)
View and export this data going back to 2022. Start your Free Trial

Net cash per share is calculated as Cash And Cash Equivalents minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Biohaven's net cash per share for the quarter that ended in Sep. 2022 was $0.43.

The historical rank and industry rank for Biohaven's Net Cash per Share or its related term are showing as below:

BHVN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 14.65   Med: 14.65   Max: 45.62
Current: 43.67

During the past 2 years, the highest Price-to-Net-Cash Ratio of Biohaven was 45.62. The lowest was 14.65. And the median was 14.65.

BHVN's Price-to-Net-Cash is ranked worse than
95.41% of 1023 companies
in the Biotechnology industry
Industry Median: 3.82 vs BHVN: 43.67

Biohaven Net Cash per Share Historical Data

The historical data trend for Biohaven's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data
Trend Dec20 Dec21
Net Cash per Share
-0.34 -0.87

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22
Net Cash per Share Premium Member Only - - -0.87 5.23 0.43

Competitive Comparison

For the Biotechnology subindustry, Biohaven's Net Cash per Share, along with its competitors' market caps and Net Cash per Share data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven Net Cash per Share Distribution

For the Biotechnology industry and Healthcare sector, Biohaven's Net Cash per Share distribution charts can be found below:

* The bar in red indicates where Biohaven's Net Cash per Share falls in comparison to its industry or sector. The grey bar indicates the Net Cash per Share's extreme value range as defined by GuruFocus.



Biohaven Net Cash per Share Calculation

In the calculation of a company's net cash, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative net cash. But sometimes a company's price may be lower than its net-cash.

Biohaven's Net Cash Per Share for the fiscal year that ended in Dec. 2021 is calculated as

Net Cash Per Share (A: Dec. 2021 )=(Cash And Cash Equivalents**-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(76.057-47.37-60)/35.823
=-0.87

Biohaven's Net Cash Per Share for the quarter that ended in Sep. 2022 is calculated as

Net Cash Per Share (Q: Sep. 2022 )=(Cash And Cash Equivalents**-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(50.668-35.43-0)/35.8326
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Note that the Cash And Cash Equivalents here include cash, cash equivalents and short-term investments.


Biohaven  (NYSE:BHVN) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener. GuruFocus also publishes a monthly Net-Net newsletter.


Biohaven Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Biohaven's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (NYSE:BHVN) Business Description

Biohaven logo
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
Executives
Robert J Hugin director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Gregory Bailey director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET UNIT# PH1N NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139

Biohaven (NYSE:BHVN) Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership